ST Xiangxue: The clinical trial application for the new drug XLS-103 injection of its subsidiary Xiangxue Life Science has obtained clinical trial approval.

Announcement from ST Xiangxue: Subsidiary Xiangxue Life Science Technology Co., Ltd. has received two "Drug Clinical Trial Approval Notices" issued by the National Medical Products Administration. The clinical registration application for XLS-103 injection of Xiangxue Life Science has been granted approval for clinical trials.